NEW YORK, April 9, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Halozyme Therapeutics, Inc. (NASDAQ: HALO), Align Technology Inc.
(NASDAQ: ALGN), Cambrex Corporation. (NYSE: CBM), Receptos, Inc.
(NASDAQ: RCPT), and Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC).
Private wealth members receive these notes ahead of publication. To
reserve complementary membership, limited openings are available
at: http://www.AnalystsReview.com/register
--
Halozyme Therapeutics, Inc. Analyst Notes
On April 4, 2014, Halozyme
Therapeutics, Inc. (Halozyme) announced that it is temporarily
halting patient enrollment and dosing of PEGPH20 in an ongoing
Phase 2 trial (Study 202) evaluating PEGPH20 in patients with
pancreatic cancer as a result of a recommendation which the Company
received from an independent Data Monitoring Committee (DMC).
According to the Company, DMC is assessing clinical data that
indicates a possible difference in the thromboembolic event rate
between the group of patients treated with PEGPH20, nab-paclitaxel
and gemcitabine versus the group of patients treated with
nab-paclitaxel and gemcitabine without PEGPH20. The Company stated
that it is halting enrollment and dosing of PEGPH20 as
precautionary actions while the DMC's full evaluation of the data
is ongoing. Commenting on the development, Dr. Helen Torley, President and CEO of the Company,
stated, "Patient safety is our first priority. We will be providing
additional information to the DMC as quickly as possible so they
can complete their assessment and we can determine next steps." The
full analyst notes on Halozyme Therapeutics, Inc. are available to
download free of charge at:
http://www.AnalystsReview.com/04092014/HALO/report.pdf
--
Align Technology Inc. Analyst Notes
On April 3, 2014, Align Technology
Inc. (Align Technology) reported that it has received notice, that
the International Trade Commission (ITC) has affirmed the
Administrative Law Judge's (ALJ) Initial Determination that the
ClearCorrect entities (ClearCorrect Operating, LLC and ClearCorrect
Pakistan (Private) Ltd.) infringe five of the patents asserted by
the Company in its ITC investigation. Align Technology stated that
the Commission ruled in favor of the Company, with regard the
patents, issued cease-and-desist orders directed to the
ClearCorrect entities, and terminated the investigation.
Roger E. George, Align Technology
Vice President and General Counsel, stated, "While we have not yet
had the opportunity to review the opinion, we have been notified
that the Commission found a violation of Section 337 based on the
finding that the ClearCorrect entities infringe at least 18 claims
of Align's patents, The ITC has spoken, and it agrees with the ALJ,
Align, and the ITC Staff Attorneys that these patent claims are
valid, and that ClearCorrect infringes them. ClearCorrect can no
longer use Align's patented process to generate infringing digital
data and then simply import that data from Pakistan to print out molds used to make
aligners in the US. We appreciate the ITC's assistance, and we will
continue to vigorously defend our patents against infringement by
domestic and foreign competitors." The full analyst notes on Align
Technology Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04092014/ALGN/report.pdf
--
Cambrex Corporation. Analyst Notes
On March 26, 2014, Cambrex
Corporation. (Cambrex) announced that the Medical Products Agency
(MPA) of Sweden has completed an
inspection of Cambrex's active pharmaceutical ingredient (API)
manufacturing facility located in Karlskoga, Sweden. According to the Company, the
inspection which was conducted in September
2013, found the site to be compliant with the principles and
guidelines of Good Manufacturing Practice (GMP) and the site's GMP
certificate was renewed. Bjarne
Sandberg, Managing Director of Cambrex Karlskoga AB, said,
"We are extremely pleased with the results of this latest MPA
inspection. The renewing of our GMP certificate demonstrates
continuing dedication to outstanding regulatory compliance at
Cambrex Karlskoga." The full analyst notes on Cambrex Corporation.
are available to download free of charge at:
http://www.AnalystsReview.com/04092014/CBM/report.pdf
--
Receptos, Inc. Analyst Notes
On April 4, 2014, Receptos, Inc.
(Receptos) stock price went down by 8.62%, closing at $37.93 per share. For the past one month, the
Receptos shares have slipped by 18.54% compared to the Nasdaq
Composite which has also lost 5.15% over the same period. The full
analyst notes on Receptos, Inc. are available to download free of
charge at:
http://www.AnalystsReview.com/04092014/RCPT/report.pdf
--
Anacor Pharmaceuticals, Inc. Analyst Notes
On March 31, 2014, Anacor
Pharmaceuticals, Inc. (Anacor) announced that the first patient has
been enrolled in the Phase 3 trial of AN2728, a novel boron-based
phosphodiesterase-4 (PDE-4) inhibitor, used towards the topical
treatment of mild-to-moderate atopic dermatitis. According to
Anacor, the Phase 3 trial comprises of two multi-center,
double-blind, vehicle-controlled studies which will enroll
approximately 750 subjects per study who will be randomized 2:1
(active:vehicle). The Company informed that both studies will be
conducted at multiple sites and enroll subjects ages two years and
older with mild-to-moderate atopic dermatitis, defined as an
Investigator Static Global Assessment (ISGA) score of 2 ("mild") or
3 ("moderate") on the ISGA 5-point scale from 0 ("clear") to 4
("severe"). Anacor added that the primary efficacy endpoint of the
study will be treatment success at Day 29, defined as an ISGA of
"Clear" or "Almost Clear" with at least a 2-grade improvement from
baseline. The full analyst notes on Anacor Pharmaceuticals, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/04092014/ANAC/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review